

**Prescription and Over-the-Counter Drug Product List**

**46TH EDITION**

**Cumulative Supplement Number 04 : April 2026**

**ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST**

ABAMETAPIR

LOTION; TOPICAL  
XEGLYZE

>D>	+ @ HATCHTECH	0.74%	N206966	001	Jul 24, 2020	Apr	CAHN
>A>	+ @ LNHC	0.74%	N206966	001	Jul 24, 2020	Apr	CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

>A>	@ QUAGEN	325MG; 50MG; 40MG; 30MG	A204649	001	Jul 08, 2020	Apr	CAHN
>D>	@ STRIDES PHARMA	325MG; 50MG; 40MG; 30MG	A204649	001	Jul 08, 2020	Apr	CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

PERCOCET

>D>	AA	!	ENDO OPERATIONS	325MG; 2.5MG	A040330	001	Jun 25, 1999	Apr	CAHN
>D>	AA	!		325MG; 5MG	A040330	002	Jun 25, 1999	Apr	CAHN
>D>		+ @		325MG; 5MG	A085106	002	Feb 06, 1981	Apr	CAHN
>D>	AA	!		325MG; 7.5MG	A040330	003	Nov 23, 2001	Apr	CAHN
>D>	AA	!		325MG; 10MG	A040330	004	Nov 23, 2001	Apr	CAHN
>A>	AA	!	OZANTRI	325MG; 2.5MG	A040330	001	Jun 25, 1999	Apr	CAHN
>A>	AA	!		325MG; 5MG	A040330	002	Jun 25, 1999	Apr	CAHN
>A>		+ @		325MG; 5MG	A085106	002	Feb 06, 1981	Apr	CAHN
>A>	AA	!		325MG; 7.5MG	A040330	003	Nov 23, 2001	Apr	CAHN
>A>	AA	!		325MG; 10MG	A040330	004	Nov 23, 2001	Apr	CAHN

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

ALBUTEROL SULFATE

>A>	AB3		CIPLA	EQ 0.09MG BASE/INH	A219409	001	Apr 22, 2026	Apr	NFTG
			VENTOLIN HFA						
>D>	BX	+	GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001	Apr	CFTG
>A>	AB3	+		EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001	Apr	CFTG

ALPELISIB

GRANULE; ORAL

VIJOICE

>A>		+	NOVARTIS	50MG/PACKET	N218466	001	Apr 24, 2024	Apr	CDFR
>D>			GRANULES; ORAL						
>D>			VIJOICE						
>D>		+	NOVARTIS	50MG/PACKET	N218466	001	Apr 24, 2024	Apr	CDFR

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION; INTRAVENOUS

INFUVITE ADULT

>D>		+	SANDOZ CANADA INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MC G/ML; 8MG/ML; 1.2MG/ML; 0.72M G/ML; 1.2MG/ML; 660	N021163	001	May 18, 2000	Apr	CFTG
>A>	AP	+		2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MC G/ML; 8MG/ML; 1.2MG/ML; 0.72M G/ML; 1.2MG/ML; 660	N021163	001	May 18, 2000	Apr	CFTG
>D>		+		2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MC G/ML; 8MG/ML; 1.2MG/ML; 0.72M G/ML; 1.2MG/ML; 660	N021163	002	Jun 16, 2003	Apr	CFTG
>A>	AP	+		2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MC G/ML; 8MG/ML; 1.2MG/ML; 0.72M G/ML; 1.2MG/ML; 660	N021163	002	Jun 16, 2003	Apr	CFTG
>A>			MULTIPLE VITAMINS INJECTION ADULT						
>A>	AP		APOTEX	2 IU/ML; 40MG/ML; 12MCG/ML;	A210273	001	Apr 09, 2026	Apr	NFTG

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION; INTRAVENOUS

>A> MULTIPLE VITAMINS INJECTION ADULT

AP 40  
IU/ML; 1MCG/ML; 3MG/ML; 120MG  
G/ML; 8MG/ML; 1.2MG/ML; 0.72MG  
G/ML; 1.2MG/ML; 660

>A> AP 2 A210672 001 Apr 09, 2026 Apr NFTG  
IU/ML; 40MG/ML; 12MCG/ML; 40  
IU/ML; 1MCG/ML; 3MG/ML; 120MG  
G/ML; 8MG/ML; 1.2MG/ML; 0.72MG  
G/ML; 1.2MG/ML; 660

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

>A> AA POM PHARMA 50MG/5ML A214178 001 Aug 20, 2021 Apr CAHN  
>D> AA SHREE HARI INTL 50MG/5ML A214178 001 Aug 20, 2021 Apr CAHN

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

>D> AB ATHEM 100MG A210215 001 Mar 10, 2020 Apr CAHN  
>A> AB POM PHARMA 100MG A210215 001 Mar 10, 2020 Apr CAHN

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

>D> AB LUPIN EQ 5MG BASE; 160MG A090245 001 Mar 30, 2015 Apr DISC  
>A> @ EQ 5MG BASE; 160MG A090245 001 Mar 30, 2015 Apr DISC  
>D> AB EQ 5MG BASE; 320MG A090245 003 Mar 30, 2015 Apr DISC  
>A> @ EQ 5MG BASE; 320MG A090245 003 Mar 30, 2015 Apr DISC  
>D> AB EQ 10MG BASE; 160MG A090245 002 Mar 30, 2015 Apr DISC  
>A> @ EQ 10MG BASE; 160MG A090245 002 Mar 30, 2015 Apr DISC  
>D> AB EQ 10MG BASE; 320MG A090245 004 Mar 30, 2015 Apr DISC  
>A> @ EQ 10MG BASE; 320MG A090245 004 Mar 30, 2015 Apr DISC

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

>D> AP NUKEMED 30mCi-300mCi/8ML (3.75-37.5mCi/ML) A204455 001 Apr 23, 2015 Apr DISC  
>A> @ 30mCi-300mCi/8ML (3.75-37.5mCi/ML) A204455 001 Apr 23, 2015 Apr DISC

ARIPIPIRAZOLE

TABLET; ORAL

ARIPIPIRAZOLE

>D> AB APOTEX 2MG A078583 001 Jul 24, 2015 Apr DISC  
>A> @ 2MG A078583 001 Jul 24, 2015 Apr DISC  
>D> AB 5MG A078583 002 Jul 24, 2015 Apr DISC  
>A> @ 5MG A078583 002 Jul 24, 2015 Apr DISC  
>D> AB 10MG A078583 003 Jul 24, 2015 Apr DISC  
>A> @ 10MG A078583 003 Jul 24, 2015 Apr DISC  
>D> AB 15MG A078583 004 Jul 24, 2015 Apr DISC  
>A> @ 15MG A078583 004 Jul 24, 2015 Apr DISC  
>D> AB 20MG A078583 005 Jul 24, 2015 Apr DISC  
>A> @ 20MG A078583 005 Jul 24, 2015 Apr DISC  
>D> AB 30MG A078583 006 Jul 24, 2015 Apr DISC  
>A> @ 30MG A078583 006 Jul 24, 2015 Apr DISC

ARTICAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYKLLX

>D> + @ AM GENOMICS EQ 8% BASE N218643 001 Aug 15, 2025 Apr CAHN  
>A> + @ THEA PHARMA EQ 8% BASE N218643 001 Aug 15, 2025 Apr CAHN



# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

## ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

>D>	@ PHARMOBEDIANT	0.025MG;2.5MG	A 085762	001	Nov 17, 1977	Apr	CAHN
>A>	@ QUAGEN	0.025MG;2.5MG	A 085762	001	Nov 17, 1977	Apr	CAHN

## AXITINIB

TABLET; ORAL

>D>	AXITINIB						
>D>	AB APOTEX	1MG	A 211650	001	Oct 30, 2025	Apr	DISC
>A>	@	1MG	A 211650	001	Oct 30, 2025	Apr	DISC
>D>	AB	5MG	A 211650	002	Oct 30, 2025	Apr	DISC
>A>	@	5MG	A 211650	002	Oct 30, 2025	Apr	DISC
	INLYTA						
>D>	AB + PF PRISM CV	1MG	N 202324	001	Jan 27, 2012	Apr	CTEC
>A>	+	1MG	N 202324	001	Jan 27, 2012	Apr	CTEC
>D>	AB +!	5MG	N 202324	002	Jan 27, 2012	Apr	CTEC
>A>	+	5MG	N 202324	002	Jan 27, 2012	Apr	CTEC

## AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

>D>	AP AMNEAL	100MG/VIAL	A 211549	001	Feb 03, 2022	Apr	DISC
>A>	@	100MG/VIAL	A 211549	001	Feb 03, 2022	Apr	DISC

## AZILSARTAN KAMEDEXOMIL

TABLET; ORAL

AZILSARTAN MEDOXOMIL

>A>	AB LUPIN	EQ 40MG MEDOXOMIL	A 214489	001	Jul 20, 2022	Apr	CMFD
>A>	AB	EQ 80MG MEDOXOMIL	A 214489	002	Jul 20, 2022	Apr	CMFD
>D>	@ LUPIN LTD	EQ 40MG MEDOXOMIL	A 214489	001	Jul 20, 2022	Apr	CMFD
>D>	@	EQ 80MG MEDOXOMIL	A 214489	002	Jul 20, 2022	Apr	CMFD
	EDARBI						
>D>	+ AZURITY	EQ 40MG MEDOXOMIL	N 200796	001	Feb 25, 2011	Apr	CTEC
>A>	AB	EQ 40MG MEDOXOMIL	N 200796	001	Feb 25, 2011	Apr	CTEC
>D>	+	EQ 80MG MEDOXOMIL	N 200796	002	Feb 25, 2011	Apr	CTEC
>A>	AB	EQ 80MG MEDOXOMIL	N 200796	002	Feb 25, 2011	Apr	CTEC

## BACLOFEN

>A>	GRANULE; ORAL						
>A>	LYVISPAH						
>A>	+ @ STRIDES PHARMA INTL	5MG/PACKET	N 215422	001	Nov 22, 2021	Apr	CDFR
>A>	+ @	10MG/PACKET	N 215422	002	Nov 22, 2021	Apr	CDFR
>A>	+ @	20MG/PACKET	N 215422	003	Nov 22, 2021	Apr	CDFR
>D>	GRANULES; ORAL						
>D>	LYVISPAH						
>D>	+ @ STRIDES PHARMA INTL	5MG/PACKET	N 215422	001	Nov 22, 2021	Apr	CDFR
>D>	+ @	10MG/PACKET	N 215422	002	Nov 22, 2021	Apr	CDFR
>D>	+ @	20MG/PACKET	N 215422	003	Nov 22, 2021	Apr	CDFR

## BENDAMUSTINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

BENDAMUSTINE HYDROCHLORIDE

>D>	+ @ DR REDDYS	100MG/4ML (25MG/ML)	N 219014	001	Jul 03, 2025	Apr	CMFD
>A>	+	100MG/4ML (25MG/ML)	N 219014	001	Jul 03, 2025	Apr	CMFD

## BENZONATATE

CAPSULE; ORAL

BENZONATATE

>D>	@ ASCENT PHARMS INC	150MG	A 211518	002	Feb 22, 2019	Apr	CMFD
>A>	AA	150MG	A 211518	002	Feb 22, 2019	Apr	CMFD
>D>	! THEPHARMANETWORK LLC	150MG	A 040627	003	Sep 24, 2014	Apr	CTEC
>A>	AA !	150MG	A 040627	003	Sep 24, 2014	Apr	CTEC

## BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPOTASTINE BESILATE

>D>	AT APOTEX	1.5%	A 206066	001	Mar 05, 2019	Apr	DISC
>A>	@	1.5%	A 206066	001	Mar 05, 2019	Apr	DISC

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

BIMATOPROST

SOLUTION/DROPS;TOPICAL

BIMATOPROST

>D>	AT	APOTEX	0.03%	A201894	001	Dec 01, 2014	Apr	DISC
>A>		@	0.03%	A201894	001	Dec 01, 2014	Apr	DISC

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

>A>	AB	MANKIND PHARMA	0.1%	A220398	001	Apr 16, 2026	Apr	NEWA
>A>	AB	MICRO LABS	0.1%	A218558	001	May 07, 2026	Apr	NEWA

BUDESONIDE; FORMOTEROL FUMARATE

AEROSOL, METERED;INHALATION

SYMBICORT AEROSPHERE

>A>		+! ASTRAZENECA	0.08MG/INH;0.0048MG/INH	N216579	002	Apr 27, 2026	Apr	NEWA
-----	--	----------------	-------------------------	---------	-----	--------------	-----	------

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED;INHALATION

BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE

>A>	AB	TEVA PHARMS USA INC	0.08MG/INH;0.0045MG/INH	A212212	001	Apr 23, 2026	Apr	NEWA
>A>	AB		0.16MG/INH;0.0045MG/INH	A212212	002	Apr 23, 2026	Apr	NEWA

BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED;INHALATION

BREZTRI AEROSPHERE

>A>		+! ASTRAZENECA AB	0.16MG/INH;0.0048MG/INH;0.018MG/INH	N212122	002	Apr 27, 2026	Apr	NEWA
-----	--	-------------------	-------------------------------------	---------	-----	--------------	-----	------

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

>A>	AP	ANTHEA PHARMA	0.25%	A220493	001	Apr 22, 2026	Apr	NEWA
>A>	AP		0.5%	A220493	002	Apr 22, 2026	Apr	NEWA
>A>	AP		0.75%	A220493	003	Apr 22, 2026	Apr	NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

>A>	AB1	YICHANG HUMANWELL	100MG	A220529	001	May 04, 2026	Apr	NEWA
>A>	AB1		150MG	A220529	002	May 04, 2026	Apr	NEWA
>A>	AB1		200MG	A220529	003	May 04, 2026	Apr	NEWA

BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

AUVELITY

>A>		+ AXSOME	105MG;30MG	N215430	002	Apr 30, 2026	Apr	NEWA
-----	--	----------	------------	---------	-----	--------------	-----	------

BUSPIRONE HYDROCHLORIDE

CAPSULE;ORAL

BUCAPSOL

>A>		EPIC PHARMA LLC	5MG	A218628	004	Apr 29, 2026	Apr	NFTG
-----	--	-----------------	-----	---------	-----	--------------	-----	------

CALCIUM GLUCONATE

SOLUTION;INTRAVENOUS

CALCIUM GLUCONATE

>A>	AP	CAPLIN	1GM/10ML (100MG/ML)	A218840	001	May 04, 2026	Apr	NEWA
>A>	AP		5GM/50ML (100MG/ML)	A218840	002	May 04, 2026	Apr	NEWA
>A>	AP		10GM/100ML (100MG/ML)	A218840	003	May 04, 2026	Apr	NEWA

CANAGLIFLOZIN

TABLET;ORAL

CANAGLIFLOZIN

>A>								
>A>	AB	APOTEX	100MG	A210449	001	Apr 14, 2026	Apr	NFTG
>A>	AB		300MG	A210449	002	Apr 14, 2026	Apr	NFTG
>A>	AB	AUROBINDO PHARMA LTD	100MG	A210386	001	Apr 20, 2026	Apr	NEWA
>A>		@	100MG	A210386	001	Apr 20, 2026	Apr	DISC
>A>	AB		300MG	A210386	002	Apr 20, 2026	Apr	NEWA
>A>		@	300MG	A210386	002	Apr 20, 2026	Apr	DISC
>D>		INVOKANA						
>D>		+ JANSSEN PHARMS	100MG	N204042	001	Mar 29, 2013	Apr	CFTG

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

CANAGLIFLOZIN

TABLET; ORAL

INVOKANA

>A>	AB	+	100MG	N204042	001	Mar 29, 2013	Apr	CFTG
>D>		+	300MG	N204042	002	Mar 29, 2013	Apr	CFTG
>A>	AB	+	300MG	N204042	002	Mar 29, 2013	Apr	CFTG

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

>D>	AP	!	SANDOZ INC	EQ 1GM BASE/VIAL	A 065204	001	May 03, 2005	Apr	DISC
>A>		@		EQ 1GM BASE/VIAL	A 065204	001	May 03, 2005	Apr	DISC
>D>	AP	!		EQ 2GM BASE/VIAL	A 065204	002	May 03, 2005	Apr	DISC
>A>		@		EQ 2GM BASE/VIAL	A 065204	002	May 03, 2005	Apr	DISC

CETIRIZINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

QUZYTTIR

>A>		+	ESTEVE	10MG/ML (10MG/ML)	N211415	001	Oct 04, 2019	Apr	CAHN
>D>		+	JDP	10MG/ML (10MG/ML)	N211415	001	Oct 04, 2019	Apr	CAHN

CETRORELIX ACETATE

POWDER; SUBCUTANEOUS

CETRORELIX ACETATE

>A>	AP		HUMANWELL	EQ 0.25MG BASE/VIAL	A218740	001	Apr 29, 2026	Apr	NEWA
-----	----	--	-----------	---------------------	---------	-----	--------------	-----	------

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

>D>		@	PIRAMAL	EQ 2MG BASE/ML	A212432	001	Mar 11, 2022	Apr	CMFD
>A>	AP			EQ 2MG BASE/ML	A212432	001	Mar 11, 2022	Apr	CMFD
>D>		@		EQ 10MG BASE/ML	A212432	002	Mar 11, 2022	Apr	CMFD
>A>	AP			EQ 10MG BASE/ML	A212432	002	Mar 11, 2022	Apr	CMFD
			CISATRACURIUM BESYLATE PRESERVATIVE FREE						
>D>		@	HAINAN POLY	EQ 2MG BASE/ML	A216539	001	Aug 27, 2024	Apr	CMFD
>A>	AP			EQ 2MG BASE/ML	A216539	001	Aug 27, 2024	Apr	CMFD
>D>		@		EQ 10MG BASE/ML	A216539	002	Aug 27, 2024	Apr	CMFD
>A>	AP			EQ 10MG BASE/ML	A216539	002	Aug 27, 2024	Apr	CMFD

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

>D>	AA		AMNEAL PHARMS	EQ 75MG BASE/5ML	A203513	001	Mar 13, 2014	Apr	DISC
>A>		@		EQ 75MG BASE/5ML	A203513	001	Mar 13, 2014	Apr	DISC

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

>D>		@	PHARMOBEDIANT	0.5MG	A 074940	001	Oct 30, 1997	Apr	CAHN
>D>		@		1MG	A 074940	002	Oct 30, 1997	Apr	CAHN
>D>		@		2MG	A 074940	003	Oct 30, 1997	Apr	CAHN
>A>		@	QUAGEN	0.5MG	A 074940	001	Oct 30, 1997	Apr	CAHN
>A>		@		1MG	A 074940	002	Oct 30, 1997	Apr	CAHN
>A>		@		2MG	A 074940	003	Oct 30, 1997	Apr	CAHN

CROTAMITON

CREAM; TOPICAL

EURAX

>D>		+	@ JOURNEY	10%	N006927	001	Jul 06, 1949	Apr	CMFD
>A>		+	!	10%	N006927	001	Jul 06, 1949	Apr	CMFD

LOTION; TOPICAL

CROTAN

>D>	AT		LEGACY PHARMA	10%	A 087204	001	Dec 16, 1981	Apr	CTEC
>A>				10%	A 087204	001	Dec 16, 1981	Apr	CTEC
>A>		!		10%	A 087204	001	Dec 16, 1981	Apr	CHRS
>D>			EURAX						
>D>	AT	+	! JOURNEY	10%	N009112	003	Apr 29, 1955	Apr	DISC
>A>		+	@	10%	N009112	003	Apr 29, 1955	Apr	DISC

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE

>D>	AP	RK PHARMA	EQ 0.4MG COPPER/ML	A217626	001	Apr 30, 2024	Apr	CAHN
>A>	AP	STIRA	EQ 0.4MG COPPER/ML	A217626	001	Apr 30, 2024	Apr	CAHN

DEFERIPRONE

TABLET; ORAL

FERRIPROX

>D>	AB	+ CHIESI	500MG	N021825	001	Oct 14, 2011	Apr	DISC
>A>		+ @	500MG	N021825	001	Oct 14, 2011	Apr	DISC

DESONIDE

AEROSOL, FOAM; TOPICAL

VERDESO

>D>		+ @ ALMIRALL	0.05%	N021978	001	Sep 19, 2006	Apr	CAHN
>A>		+ @ GENUS	0.05%	N021978	001	Sep 19, 2006	Apr	CAHN

LOTION; TOPICAL

DESONIDE

>D>		@ PAI HOLDINGS PHARM	0.05%	A207855	001	Sep 28, 2017	Apr	CAHN
>A>		@ VERTICE	0.05%	A207855	001	Sep 28, 2017	Apr	CAHN

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

>D>		@ SCIEGEN PHARMS	0.05%	A203787	001	Jan 06, 2017	Apr	CMFD
>A>	AB		0.05%	A203787	001	Jan 06, 2017	Apr	CMFD
>D>		@	0.25%	A203234	001	Jun 12, 2015	Apr	CMFD
>A>	AB		0.25%	A203234	001	Jun 12, 2015	Apr	CMFD

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

>A>	AP	BAXTER HLTHCARE CORP	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A208103	001	Apr 15, 2026	Apr	NEWA
>D>	AP	CAPLIN	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A091465	001	Jun 14, 2016	Apr	DISC
>A>		@	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A091465	001	Jun 14, 2016	Apr	DISC

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

>D>	AB	MEDICAP LABS	5MG	A078992	001	Nov 23, 2021	Apr	CAHN
>D>	AB		10MG	A078992	002	Nov 23, 2021	Apr	CAHN
>D>	AB		15MG	A078992	003	Nov 18, 2013	Apr	CAHN
>D>	AB		30MG	A078992	004	Nov 18, 2013	Apr	CAHN
>D>	AB		20MG	A078992	005	Nov 23, 2021	Apr	CAHN
>D>	AB		40MG	A078992	006	Nov 23, 2021	Apr	CAHN
>A>	AB	PLATINUM	5MG	A078992	001	Nov 23, 2021	Apr	CAHN
>A>	AB		10MG	A078992	002	Nov 23, 2021	Apr	CAHN
>A>	AB		15MG	A078992	003	Nov 18, 2013	Apr	CAHN
>A>	AB		30MG	A078992	004	Nov 18, 2013	Apr	CAHN
>A>	AB		20MG	A078992	005	Nov 23, 2021	Apr	CAHN
>A>	AB		40MG	A078992	006	Nov 23, 2021	Apr	CAHN

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMPHETAMINE SULFATE

>D>		@ PHARMOBEDIENT	5MG	A206735	001	Jan 27, 2016	Apr	CAHN
>D>		@	10MG	A206735	002	Jan 27, 2016	Apr	CAHN
>D>		@	15MG	A206735	003	Jan 27, 2016	Apr	CAHN
>A>		@ QUAGEN	5MG	A206735	001	Jan 27, 2016	Apr	CAHN
>A>		@	10MG	A206735	002	Jan 27, 2016	Apr	CAHN
>A>		@	15MG	A206735	003	Jan 27, 2016	Apr	CAHN

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

>A>	<u>DORAVIRINE; ISLATRAVIR</u>									
>A>	TABLET; ORAL									
>A>	IDVNSO									
>A>		+! MSD	100MG;0.25MG	N216964	001	Apr 20, 2026	Apr	NEWA		
	<u>DOXEPIN HYDROCHLORIDE</u>									
	CREAM; TOPICAL									
	DOXEPIN HYDROCHLORIDE									
>A>	AB	SUN PHARMA CANADA	5%	A213919	001	Apr 28, 2026	Apr	NEWA		
	<u>DOXERCALCIFEROL</u>									
	INJECTABLE; INJECTION									
	DOXERCALCIFEROL									
>D>	AP	CAPLIN	4MCG/2ML (2MCG/ML)	A200926	001	Feb 04, 2014	Apr	DISC		
>A>		@	4MCG/2ML (2MCG/ML)	A200926	001	Feb 04, 2014	Apr	DISC		
>A>			2MCG/ML (2MCG/ML)	A200926	002	Sep 04, 2014	Apr	NEWA		
>A>		@	2MCG/ML (2MCG/ML)	A200926	002	Sep 04, 2014	Apr	DISC		
	<u>DOXYCYCLINE HYCLATE</u>									
	TABLET, DELAYED RELEASE; ORAL									
>D>	DORYX									
>D>		+ MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr	DISC		
>A>		+ @	EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr	DISC		
>D>	AB	+	EQ 200MG BASE	N050795	005	Apr 11, 2013	Apr	DISC		
>A>		+ @	EQ 200MG BASE	N050795	005	Apr 11, 2013	Apr	DISC		
	<u>EDARAVONE</u>									
	SOLUTION; INTRAVENOUS									
	EDARAVONE									
>D>	AP	DR REDDYS	60MG/100ML (0.6MG/ML)	A215917	001	May 06, 2024	Apr	DISC		
>A>		@	60MG/100ML (0.6MG/ML)	A215917	001	May 06, 2024	Apr	DISC		
>D>	AP	GLAND	60MG/100ML (0.6MG/ML)	A216199	002	May 06, 2024	Apr	DISC		
>A>		@	60MG/100ML (0.6MG/ML)	A216199	002	May 06, 2024	Apr	DISC		
>D>	AP	! PHARMOBEDIENT	60MG/100ML (0.6MG/ML)	A217565	002	Oct 31, 2024	Apr	CTEC		
>A>		!	60MG/100ML (0.6MG/ML)	A217565	002	Oct 31, 2024	Apr	CTEC		
	RADICAVA									
>A>		+ @ SHIONOGI	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Apr	CAHN		
>A>	AP	+	60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Apr	CAHN		
>A>		+ @	60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Apr	DISC		
>D>		+ @ TANABE PHARMA	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Apr	CAHN		
>D>	AP	+	60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Apr	CAHN		
	SUSPENSION; ORAL									
	RADICAVA ORS									
>D>		+! KK BCJ-94	105MG/5ML	N215446	001	May 12, 2022	Apr	CAHN		
>A>		+! SHIONOGI	105MG/5ML	N215446	001	May 12, 2022	Apr	CAHN		
	<u>ELEXACFTOR, IVACFTOR, TEZACFTOR; IVACFTOR</u>									
>A>	GRANULE; ORAL									
>A>	TRIKAFTA (COPACKAGED)									
>A>		+ VERTEX PHARMS INC	80MG, 60MG, 40MG;59.5MG	N217660	001	Apr 26, 2023	Apr	CDFR		
>A>		+!	100MG, 75MG, 50MG;75MG	N217660	002	Apr 26, 2023	Apr	CDFR		
>D>	GRANULES; ORAL									
>D>	TRIKAFTA (COPACKAGED)									
>D>		+ VERTEX PHARMS INC	80MG, 60MG, 40MG;59.5MG	N217660	001	Apr 26, 2023	Apr	CDFR		
>D>		+!	100MG, 75MG, 50MG;75MG	N217660	002	Apr 26, 2023	Apr	CDFR		
	<u>ELTROMBOPAG OLAMINE</u>									
	TABLET; ORAL									
	ELTROMBOPAG OLAMINE									
>A>	AB	AIZANT	EQ 12.5MG ACID	A220660	001	Apr 28, 2026	Apr	NEWA		
>A>	AB		EQ 25MG ACID	A220660	002	Apr 28, 2026	Apr	NEWA		
>A>	AB		EQ 50MG ACID	A220660	003	Apr 28, 2026	Apr	NEWA		
>A>	AB		EQ 75MG ACID	A220660	004	Apr 28, 2026	Apr	NEWA		
>A>	AB	HIKMA	EQ 12.5MG ACID	A220033	001	Apr 08, 2026	Apr	CAHN		
>A>	AB		EQ 25MG ACID	A220033	002	Apr 08, 2026	Apr	CAHN		
>A>	AB		EQ 50MG ACID	A220033	003	Apr 08, 2026	Apr	CAHN		
>A>	AB		EQ 75MG ACID	A220033	004	Apr 08, 2026	Apr	CAHN		
>D>	AB	ZENARA	EQ 12.5MG ACID	A220033	001	Apr 08, 2026	Apr	CAHN		
>D>	AB		EQ 25MG ACID	A220033	002	Apr 08, 2026	Apr	CAHN		
>D>	AB		EQ 50MG ACID	A220033	003	Apr 08, 2026	Apr	CAHN		

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

ELTROMBOPAG OLAMINE

TABLET; ORAL  
ELTROMBOPAG OLAMINE

>D> AB EQ 75MG ACID A220033 004 Apr 08, 2026 Apr CAHN

ENSIFENTRINE

SUSPENSION; INHALATION  
OHTUVAYRE

>A> +! MSD 3MG/2.5ML N217389 001 Jun 26, 2024 Apr CAHN  
>D> +! VERONA PHARMA 3MG/2.5ML N217389 001 Jun 26, 2024 Apr CAHN

ENZALUTAMIDE

TABLET; ORAL

>A> ENZALUTAMIDE  
>A> AB SANDOZ 40MG A216068 001 Apr 20, 2026 Apr NFTG  
>A> AB 80MG A216068 002 Apr 20, 2026 Apr NFTG  
XTANDI  
>D> + ASTELLAS 40MG N213674 001 Aug 04, 2020 Apr CFTG  
>A> AB + 40MG N213674 001 Aug 04, 2020 Apr CFTG  
>D> +! 80MG N213674 002 Aug 04, 2020 Apr CFTG  
>A> AB +! 80MG N213674 002 Aug 04, 2020 Apr CFTG

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC  
EPINASTINE HYDROCHLORIDE

>D> AT APOTEX 0.05% A090919 001 Oct 31, 2011 Apr DISC  
>A> @ 0.05% A090919 001 Oct 31, 2011 Apr DISC  
>D> AT ! SOMERSET THERAPS LLC 0.05% A090951 001 Oct 31, 2011 Apr CTEC  
>A> ! 0.05% A090951 001 Oct 31, 2011 Apr CTEC

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION  
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

>D> @ WEST-WARD PHARMS INT 0.01MG/ML;1% A080406 001 Mar 13, 1972 Apr CRLD  
>A> + @ 0.01MG/ML;1% A080406 001 Mar 13, 1972 Apr CRLD

EPLONTERSEN SODIUM

SOLUTION; SUBCUTANEOUS  
WAINUA

>A> +! ASTRAZENECA AB EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML) N217388 002 Apr 15, 2026 Apr NEWA

ESCITALOPRAM OXALATE

TABLET; ORAL  
ESCITALOPRAM OXALATE

>A> AB MICRO LABS EQ 5MG BASE A091655 001 Apr 22, 2026 Apr NEWA  
>A> AB EQ 10MG BASE A091655 002 Apr 22, 2026 Apr NEWA  
>A> AB EQ 20MG BASE A091655 003 Apr 22, 2026 Apr NEWA

ESZOPICLONE

TABLET; ORAL  
ESZOPICLONE

>D> AB LUPIN LTD 1MG A091124 001 Sep 13, 2011 Apr DISC  
>A> @ 1MG A091124 001 Sep 13, 2011 Apr DISC  
>D> AB 2MG A091124 002 Sep 13, 2011 Apr DISC  
>A> @ 2MG A091124 002 Sep 13, 2011 Apr DISC  
>D> AB 3MG A091124 003 Sep 13, 2011 Apr DISC  
>A> @ 3MG A091124 003 Sep 13, 2011 Apr DISC

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28  
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

>D> AB XIROMED 0.05MG;1MG A204704 001 Feb 09, 2016 Apr CHRS  
>A> AB ! 0.05MG;1MG A204704 001 Feb 09, 2016 Apr CHRS  
>D> KELNOR 1/50  
>D> AB ! WATSON LABS 0.05MG;1MG A072723 001 Dec 30, 1991 Apr DISC  
>A> @ 0.05MG;1MG A072723 001 Dec 30, 1991 Apr DISC

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

>D> MYZILRA  
 >D> AB PH HEALTH 0.03MG, 0.04MG, 0.03MG; 0.05M A 077502 001 Nov 23, 2011 Apr DISC  
 G, 0.075MG, 0.125MG  
 >A> @ 0.03MG, 0.04MG, 0.03MG; 0.05M A 077502 001 Nov 23, 2011 Apr DISC  
 G, 0.075MG, 0.125MG

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

>D> GILDAGIA  
 >D> AB PH HEALTH 0.035MG; 0.4MG A 078376 001 Nov 06, 2012 Apr DISC  
 >A> @ 0.035MG; 0.4MG A 078376 001 Nov 06, 2012 Apr DISC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

>D> GILDESS 24 FE  
 >D> AB PH HEALTH 0.02MG; 1MG A 090293 001 Dec 01, 2014 Apr DISC  
 >A> @ 0.02MG; 1MG A 090293 001 Dec 01, 2014 Apr DISC

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

>D> PREVIFEM  
 >D> AB PH HEALTH 0.035MG; 0.25MG A 076334 001 Jan 09, 2004 Apr DISC  
 >A> @ 0.035MG; 0.25MG A 076334 001 Jan 09, 2004 Apr DISC

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

>D> AB HERITAGE PHARMS INC 250MG A 200892 001 Sep 25, 2012 Apr DISC  
 >A> @ 250MG A 200892 001 Sep 25, 2012 Apr DISC

FERUMOXYTOL

SOLUTION; INTRAVENOUS

FERABRIGHT

>A> +! AZURITY EQ 300MG IRON/10ML (EQ N219868 001 Oct 16, 2025 Apr CAHN  
 30MG IRON/ML)  
 >A> +! EQ 510MG IRON/17ML (EQ N219868 002 Oct 16, 2025 Apr CAHN  
 30MG IRON/ML)  
 >D> +! COVIS EQ 300MG IRON/10ML (EQ N219868 001 Oct 16, 2025 Apr CAHN  
 30MG IRON/ML)  
 >D> +! EQ 510MG IRON/17ML (EQ N219868 002 Oct 16, 2025 Apr CAHN  
 30MG IRON/ML)

FERAHEME

>A> AB +! AZURITY EQ 510MG IRON/17ML (EQ N022180 001 Jun 30, 2009 Apr CAHN  
 30MG IRON/ML)  
 >D> AB +! COVIS EQ 510MG IRON/17ML (EQ N022180 001 Jun 30, 2009 Apr CAHN  
 30MG IRON/ML)

FINAFLOXACIN

SUSPENSION/DROPS; OTIC

XTORO

>D> + @ FONSECA BIOSCIENCES 0.3% N206307 001 Dec 17, 2014 Apr CMFD  
 >A> +! 0.3% N206307 001 Dec 17, 2014 Apr CMFD

FINGOLIMOD HYDROCHLORIDE

CAPSULE; ORAL

FINGOLIMOD HYDROCHLORIDE

>A> AB ALEMBIC EQ 0.5MG BASE A 207974 001 Apr 24, 2026 Apr NEWA

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

>A> AB OMSAV PHARMA 50MG A 218093 001 Apr 22, 2026 Apr NEWA  
 >A> AB 100MG A 218093 002 Apr 22, 2026 Apr NEWA  
 >A> AB 150MG A 218093 003 Apr 22, 2026 Apr NEWA

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

>D> NUKEMED 4-500mCi/ML A 203911 001 Apr 22, 2015 Apr DISC  
 >A> @ 4-500mCi/ML A 203911 001 Apr 22, 2015 Apr DISC

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

FLUORESCHEIN SODIUM

INJECTABLE; INTRAVENOUS

FLUORESCHEIN SODIUM

>A>	AP	BPI LABS	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A220046	001	Apr 30, 2026	Apr	NEWA
>D>		! NEXUS	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	Apr	CHRS
>A>			EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	Apr	CHRS

FLUOXETINE HYDROCHLORIDE

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

>D>	AA	AUROBINDO PHARMA	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009	Apr	CHRS
>A>	AA	!	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009	Apr	CHRS
>D>	AA	! PHARM ASSOC	EQ 20MG BASE/5ML	A076015	001	Jan 30, 2002	Apr	DISC
>A>		@	EQ 20MG BASE/5ML	A076015	001	Jan 30, 2002	Apr	DISC

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

>A>	AB	APPCO	100MG	A220328	001	Apr 30, 2026	Apr	NEWA
>A>	AB		150MG	A220328	002	Apr 30, 2026	Apr	NEWA

FULVESTRANT

SOLUTION; INTRAMUSCULAR

CLIGAVYX

>A>		@ AVYXA HOLDINGS	250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019	Apr	CTNA
>D>		FULVESTRANT						
>D>		@ AVYXA HOLDINGS	250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019	Apr	CTNA

GEFITINIB

TABLET; ORAL

GEFITINIB

>D>	AB	CIPLA	250MG	A211826	001	May 16, 2025	Apr	DISC
>A>		@	250MG	A211826	001	May 16, 2025	Apr	DISC

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

GLYCEROL PHENYLBUTYRATE

>A>	AA	AUROBINDO PHARMA	1.1GM/ML	A220313	001	Apr 15, 2026	Apr	NEWA
>A>	AA	LUPIN	1.1GM/ML	A207694	001	Apr 30, 2026	Apr	NEWA
>A>	AA	MSN	1.1GM/ML	A219540	001	Apr 15, 2026	Apr	NEWA
>A>	AA	NAVINTA LLC	1.1GM/ML	A220568	001	Apr 23, 2026	Apr	NEWA
>A>	AA	TEVA PHARMS INC	1.1GM/ML	A218738	001	Apr 15, 2026	Apr	NEWA

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

>A>	AP	NIVAGEN PHARMS INC	0.2MG/ML	A212591	001	Oct 13, 2021	Apr	CAHN
>D>	AP	UMEDICA	0.2MG/ML	A212591	001	Oct 13, 2021	Apr	CAHN

GLYCOPYRRONIUM TOSYLATE

CLOTH; TOPICAL

GLYCOPYRRONIUM TOSYLATE

>D>								
>D>	AB	PADAGIS US	EQ 2.4% BASE	A214448	001	Apr 03, 2026	Apr	DISC
>A>		@	EQ 2.4% BASE	A214448	001	Apr 03, 2026	Apr	DISC
		QBREXZA						
>D>	AB	+! JOURNEY	EQ 2.4% BASE	N210361	001	Jun 28, 2018	Apr	CTEC
>A>		+!	EQ 2.4% BASE	N210361	001	Jun 28, 2018	Apr	CTEC

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

>D>	AB	MYLAN	20MG	A070278	003	Jul 16, 2009	Apr	DISC
>A>		@	20MG	A070278	003	Jul 16, 2009	Apr	DISC

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

>A>	@	CHARTWELL RX	12.5MG;150MG	A201524	001	Feb 27, 2013	Apr	CAHN
>A>	@		12.5MG;300MG	A201524	002	Feb 27, 2013	Apr	CAHN
>D>	@	LUPIN LTD	12.5MG;150MG	A201524	001	Feb 27, 2013	Apr	CAHN
>D>	@		12.5MG;300MG	A201524	002	Feb 27, 2013	Apr	CAHN

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

>A>	AB	MICRO LABS	12.5MG;20MG	A206371	001	Apr 13, 2026	Apr	NEWA
>A>	AB		12.5MG;40MG	A206371	002	Apr 13, 2026	Apr	NEWA
>A>	AB		25MG;40MG	A206371	003	Apr 13, 2026	Apr	NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

>A>	AB	SCIEGEN PHARMS	12.5MG;80MG	A204687	001	Apr 23, 2026	Apr	NEWA
>A>	AB		12.5MG;160MG	A204687	002	Apr 23, 2026	Apr	NEWA
>A>	AB		12.5MG;320MG	A204687	003	Apr 23, 2026	Apr	NEWA
>A>	AB		25MG;160MG	A204687	004	Apr 23, 2026	Apr	NEWA
>A>	AB		25MG;320MG	A204687	005	Apr 23, 2026	Apr	NEWA

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE;INJECTION

HYDROCORTISONE SODIUM SUCCINATE

>A>	AP	ZYDUS PHARMS	EQ 100MG BASE/VIAL	A217191	001	May 07, 2026	Apr	NEWA
-----	----	--------------	--------------------	---------	-----	--------------	-----	------

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

DILAUDID-HP

>D>		+ @ FRESENIUS KABI USA	10MG/ML	N019034	001	Jan 11, 1984	Apr	CMFD
>A>	AP	+!	10MG/ML	N019034	001	Jan 11, 1984	Apr	CMFD

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

>D>	AB	AMNEAL PHARM	10MG	A040808	001	Sep 24, 2008	Apr	DISC
>A>		@	10MG	A040808	001	Sep 24, 2008	Apr	DISC
>D>	AB		25MG	A040808	002	Sep 24, 2008	Apr	DISC
>A>		@	25MG	A040808	002	Sep 24, 2008	Apr	DISC
>D>	AB		50MG	A040808	003	Sep 24, 2008	Apr	DISC
>A>		@	50MG	A040808	003	Sep 24, 2008	Apr	DISC

ICOSAPENT ETHYL

CAPSULE;ORAL

ICOSAPENT ETHYL

>D>	AB	PHARMOBEDIANT	1GM	A218994	001	Dec 20, 2024	Apr	CAHN
>A>	AB	TORRENT	1GM	A218994	001	Dec 20, 2024	Apr	CAHN

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE;INJECTION

INDIUM IN-111 PENTETREOTIDE KIT

>D>								
>D>	AP	SUN PHARM INDS INC	3mCi/ML	A212785	001	Jul 01, 2024	Apr	DISC
>A>		@	3mCi/ML	A212785	001	Jul 01, 2024	Apr	DISC
		OCTREOSCAN						
>D>	AP	+! CURIUM	3mCi/ML	N020314	001	Jun 02, 1994	Apr	CTEC
>A>		+!	3mCi/ML	N020314	001	Jun 02, 1994	Apr	CTEC

ISOSORBIDE MONONITRATE

TABLET;ORAL

ISOSORBIDE MONONITRATE

>A>	AB	ANI PHARMS	10MG	A075147	002	Mar 27, 2026	Apr	NEWA
-----	----	------------	------	---------	-----	--------------	-----	------

KETAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

KETAMINE HYDROCHLORIDE

>D>	AP	CAPLIN	EQ 10MG BASE/ML	A217858	001	Aug 07, 2025	Apr	DISC
>A>		@	EQ 10MG BASE/ML	A217858	001	Aug 07, 2025	Apr	DISC

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

KETOROLAC TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

ACULAR LS

>D>	AT	+	ABBVIE	0.4%	N021528	001	May 30, 2003	Apr	CTEC
>A>			+	0.4%	N021528	001	May 30, 2003	Apr	CTEC
KETOROLAC TROMETHAMINE									
>D>	AT		APOTEX	0.4%	A077308	001	Nov 05, 2009	Apr	DISC
>A>			@	0.4%	A077308	001	Nov 05, 2009	Apr	DISC

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

>D>	AB		PH HEALTH	25MG	A201791	001	Jan 18, 2013	Apr	DISC
>A>			@	25MG	A201791	001	Jan 18, 2013	Apr	DISC
>D>	AB			50MG	A201791	002	Jan 18, 2013	Apr	DISC
>A>			@	50MG	A201791	002	Jan 18, 2013	Apr	DISC
>D>	AB			100MG	A201791	003	Jan 18, 2013	Apr	DISC
>A>			@	100MG	A201791	003	Jan 18, 2013	Apr	DISC
>D>	AB			200MG	A201791	004	Jan 18, 2013	Apr	DISC
>A>			@	200MG	A201791	004	Jan 18, 2013	Apr	DISC
>D>	AB			250MG	A201791	005	Jan 18, 2013	Apr	DISC
>A>			@	250MG	A201791	005	Jan 18, 2013	Apr	DISC
>D>	AB			300MG	A201791	006	Jan 18, 2013	Apr	DISC
>A>			@	300MG	A201791	006	Jan 18, 2013	Apr	DISC

TABLET;ORAL

LAMOTRIGINE

>D>	AB		LUPIN LTD	25MG	A078691	001	Jun 01, 2010	Apr	DISC
>A>			@	25MG	A078691	001	Jun 01, 2010	Apr	DISC
>D>	AB			100MG	A078691	002	Jun 01, 2010	Apr	DISC
>A>			@	100MG	A078691	002	Jun 01, 2010	Apr	DISC
>D>	AB			150MG	A078691	003	Jun 01, 2010	Apr	DISC
>A>			@	150MG	A078691	003	Jun 01, 2010	Apr	DISC
>D>	AB			200MG	A078691	004	Jun 01, 2010	Apr	DISC
>A>			@	200MG	A078691	004	Jun 01, 2010	Apr	DISC

LEUCOVORIN CALCIUM

TABLET;ORAL

LEUCOVORIN CALCIUM

>A>	AB		INGENUS PHARMS LLC	EQ 5MG BASE	A211132	001	Jul 30, 2020	Apr	CAHN
>A>	AB			EQ 10MG BASE	A211132	002	Jul 30, 2020	Apr	CAHN
>A>	AB			EQ 15MG BASE	A211132	003	Jul 30, 2020	Apr	CAHN
>A>	AB			EQ 25MG BASE	A211132	004	Jul 30, 2020	Apr	CAHN
>D>	AB		NOVAST LABS	EQ 5MG BASE	A211132	001	Jul 30, 2020	Apr	CAHN
>D>	AB			EQ 10MG BASE	A211132	002	Jul 30, 2020	Apr	CAHN
>D>	AB			EQ 15MG BASE	A211132	003	Jul 30, 2020	Apr	CAHN
>D>	AB			EQ 25MG BASE	A211132	004	Jul 30, 2020	Apr	CAHN

LEVOTHYROXINE SODIUM

TABLET;ORAL

EUTHYROX

>D>	AB2		EMD SERONO INC	0.025MG	N021292	001	May 31, 2002	Apr	DISC
>A>			@	0.025MG	N021292	001	May 31, 2002	Apr	DISC
>D>	AB2			0.05MG	N021292	002	May 31, 2002	Apr	DISC
>A>			@	0.05MG	N021292	002	May 31, 2002	Apr	DISC
>D>	AB2			0.075MG	N021292	003	May 31, 2002	Apr	DISC
>A>			@	0.075MG	N021292	003	May 31, 2002	Apr	DISC
>D>	AB2			0.088MG	N021292	004	May 31, 2002	Apr	DISC
>A>			@	0.088MG	N021292	004	May 31, 2002	Apr	DISC
>D>	AB2			0.1MG	N021292	005	May 31, 2002	Apr	DISC
>A>			@	0.1MG	N021292	005	May 31, 2002	Apr	DISC
>D>	AB2			0.112MG	N021292	006	May 31, 2002	Apr	DISC
>A>			@	0.112MG	N021292	006	May 31, 2002	Apr	DISC
>D>	AB2			0.125MG	N021292	007	May 31, 2002	Apr	DISC
>A>			@	0.125MG	N021292	007	May 31, 2002	Apr	DISC
>D>	AB2			0.137MG	N021292	008	May 31, 2002	Apr	DISC
>A>			@	0.137MG	N021292	008	May 31, 2002	Apr	DISC
>D>	AB2			0.15MG	N021292	009	May 31, 2002	Apr	DISC
>A>			@	0.15MG	N021292	009	May 31, 2002	Apr	DISC
>D>	AB2			0.175MG	N021292	010	May 31, 2002	Apr	DISC

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

LEVOTHYROXINE SODIUM

TABLET; ORAL

EUTHYROX

>A>	@		0.175MG	N021292	010	May 31, 2002	Apr	DISC
>D>	AB2		0.2MG	N021292	011	May 31, 2002	Apr	DISC
>A>	@		0.2MG	N021292	011	May 31, 2002	Apr	DISC

MACITENTAN

TABLET; ORAL

MACITENTAN

>D>	@	SEASONS BIOTECH	10MG	A211026	001	Dec 03, 2025	Apr	CMFD
>A>	AB		10MG	A211026	001	Dec 03, 2025	Apr	CMFD
>D>	@	TORRENT	10MG	A211107	001	Aug 05, 2024	Apr	CMFD
>A>	AB		10MG	A211107	001	Aug 05, 2024	Apr	CMFD
>D>	@	ZYDUS LIFESCIENCES	10MG	A211224	001	Apr 06, 2021	Apr	CMFD
>A>	AB		10MG	A211224	001	Apr 06, 2021	Apr	CMFD

MARAVIROC

TABLET; ORAL

MARAVIROC

>D>	AB	RHODES PHARMS	150MG	A216143	001	Nov 04, 2025	Apr	DISC
>A>	@		150MG	A216143	001	Nov 04, 2025	Apr	DISC
>D>	AB		300MG	A216143	002	Nov 04, 2025	Apr	DISC
>A>	@		300MG	A216143	002	Nov 04, 2025	Apr	DISC

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

>A>	@	ALLIED	500MG	A215629	001	Jun 20, 2023	Apr	CAHN
>A>	@		1GM	A215629	002	Jun 20, 2023	Apr	CAHN
>D>	AB1	MEDICAP LABS	500MG	A202306	001	Feb 23, 2017	Apr	CAHN
>D>	AB		750MG	A202306	002	Feb 23, 2017	Apr	CAHN
>A>	AB1	PLATINUM	500MG	A202306	001	Feb 23, 2017	Apr	CAHN
>A>	AB		750MG	A202306	002	Feb 23, 2017	Apr	CAHN
>D>	@	RK PHARMA	500MG	A215629	001	Jun 20, 2023	Apr	CAHN
>D>	@		1GM	A215629	002	Jun 20, 2023	Apr	CAHN
>A>	@	SENORES PHARMS	500MG	A215629	001	Jun 20, 2023	Apr	CAHN
>A>	@		1GM	A215629	002	Jun 20, 2023	Apr	CAHN

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

>A>	AB	APOTEX	500MG;EQ 50MG BASE	A202426	001	Apr 30, 2026	Apr	NEWA
>A>	AB		1GM;EQ 50MG BASE	A202426	002	Apr 30, 2026	Apr	NEWA

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

>D>	@	ATHEM	25MG	A040102	001	Aug 28, 1996	Apr	CAHN
>D>	@		50MG	A040102	002	Aug 28, 1996	Apr	CAHN
>A>	@	POM PHARMA	25MG	A040102	001	Aug 28, 1996	Apr	CAHN
>A>	@		50MG	A040102	002	Aug 28, 1996	Apr	CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM

>A>	AP	ALEMBIC	EQ 50MG BASE/2ML (EQ 25MG	A220225	001	Apr 15, 2026	Apr	NEWA
			BASE/ML)					
>A>	AP		EQ 1GM BASE/40ML (EQ 25MG	A220225	002	Apr 15, 2026	Apr	NEWA
			BASE/ML)					
>A>	AP	HETERO LABS LTD VI	EQ 50MG BASE/2ML (EQ 25MG	A219865	001	Apr 30, 2026	Apr	NEWA
			BASE/ML)					
>D>	!	HIKMA	EQ 200MG BASE/8ML (EQ 25MG	A089342	001	Sep 16, 1986	Apr	CTEC
			BASE/ML)					
>A>	AP	!	EQ 200MG BASE/8ML (EQ 25MG	A089342	001	Sep 16, 1986	Apr	CTEC
			BASE/ML)					
			METHOTREXATE SODIUM PRESERVATIVE FREE					
>D>	@	EUGIA PHARMA SPECLTS	EQ 50MG BASE/2ML (EQ 25MG	A201529	001	Mar 29, 2012	Apr	CMFD
			BASE/ML)					
>A>	AP		EQ 50MG BASE/2ML (EQ 25MG	A201529	001	Mar 29, 2012	Apr	CMFD
			BASE/ML)					
>D>	@		EQ 100MG BASE/4ML (EQ 25MG	A201529	002	Mar 29, 2012	Apr	CMFD

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

BASE/ML)

>A>	AP		EQ 100MG BASE/4ML (EQ 25MG A201529 002 Mar 29, 2012 Apr CMFD
			BASE/ML)
>D>	@		EQ 200MG BASE/8ML (EQ 25MG A201529 003 Mar 29, 2012 Apr CMFD
			BASE/ML)
>A>	AP		EQ 200MG BASE/8ML (EQ 25MG A201529 003 Mar 29, 2012 Apr CMFD
			BASE/ML)
>D>	@		EQ 250MG BASE/10ML (EQ A201529 004 Mar 29, 2012 Apr CMFD
			25MG BASE/ML)
>A>	AP		EQ 250MG BASE/10ML (EQ A201529 004 Mar 29, 2012 Apr CMFD
			25MG BASE/ML)

METHYLDOPA

TABLET; ORAL

METHYLDOPA

>A>	@	QUAGEN	125MG	A 070535 001 Jan 02, 1987 Apr CAHN
>A>	@		250MG	A 070536 001 Jan 02, 1987 Apr CAHN
>A>	@		500MG	A 070537 001 Jan 02, 1987 Apr CAHN
>D>	@	STRIDES PHARMA INTL	125MG	A 070535 001 Jan 02, 1987 Apr CAHN
>D>	@		250MG	A 070536 001 Jan 02, 1987 Apr CAHN
>D>	@		500MG	A 070537 001 Jan 02, 1987 Apr CAHN

METHYLPHENIDATE HYDROCHLORIDE

TABLET, CHEWABLE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	@	QUAGEN	2.5MG	A 204954 001 Jan 26, 2017 Apr CAHN
>A>	@		5MG	A 204954 002 Jan 26, 2017 Apr CAHN
>A>	@		10MG	A 204954 003 Jan 26, 2017 Apr CAHN
>D>	@	STRIDES PHARMA	2.5MG	A 204954 001 Jan 26, 2017 Apr CAHN
>D>	@		5MG	A 204954 002 Jan 26, 2017 Apr CAHN
>D>	@		10MG	A 204954 003 Jan 26, 2017 Apr CAHN

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

>D>	AB	IMPAX PHARMS	2.5MG	A 076449 001 May 27, 2004 Apr DISC
>A>	@		2.5MG	A 076449 001 May 27, 2004 Apr DISC
>D>	AB		5MG	A 076449 002 May 27, 2004 Apr DISC
>A>	@		5MG	A 076449 002 May 27, 2004 Apr DISC
>D>	AB		10MG	A 076449 003 Dec 16, 2005 Apr DISC
>A>	@		10MG	A 076449 003 Dec 16, 2005 Apr DISC

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

>D>	AB	CHARTWELL RX	EQ 45MG BASE	A 091424 001 Nov 30, 2011 Apr CAHN
>D>	AB		EQ 55MG BASE	A 091424 002 Nov 30, 2011 Apr CAHN
>D>	AB		EQ 90MG BASE	A 091424 003 Nov 30, 2011 Apr CAHN
>D>	AB		EQ 135MG BASE	A 091424 004 Nov 30, 2011 Apr CAHN
>A>	AB	LUPIN	EQ 45MG BASE	A 091424 001 Nov 30, 2011 Apr CAHN
>A>	AB		EQ 55MG BASE	A 091424 002 Nov 30, 2011 Apr CAHN
>A>	AB		EQ 90MG BASE	A 091424 003 Nov 30, 2011 Apr CAHN
>A>	AB		EQ 135MG BASE	A 091424 004 Nov 30, 2011 Apr CAHN

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL

MIRABEGRON

>A>	AB	DEVA HOLDING AS	25MG	A 219941 001 May 01, 2026 Apr NEWA
>A>	AB		50MG	A 219941 002 May 01, 2026 Apr NEWA

MOMETASONE FUROATE

OINTMENT; TOPICAL

MOMETASONE FUROATE

>D>	@	ENCUBE	0.1%	A 076481 001 Nov 14, 2003 Apr CMFD
>A>	AB		0.1%	A 076481 001 Nov 14, 2003 Apr CMFD

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

## MOXIFLOXACIN HYDROCHLORIDE

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

>D>	AB	TORRENT	EQ 400MG BASE	A 200160	001	Apr 03, 2014	Apr	DISC
>A>		@	EQ 400MG BASE	A 200160	001	Apr 03, 2014	Apr	DISC

## NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

>D>	AA	AARXION ANDA HLDING	500MG	A 065220	001	Jul 28, 2006	Apr	CAHN
>A>	AA	SOLARIS PHARMA CORP	500MG	A 065220	001	Jul 28, 2006	Apr	CAHN

## NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

>D>	AB2	NOVAST LABS	90MG	A 210614	003	Mar 12, 2019	Apr	CHRS
>A>	AB2	!	90MG	A 210614	003	Mar 12, 2019	Apr	CHRS
		PROCARDIA XL						
>D>	AB2	+! PFIZER	90MG	N 019684	003	Sep 06, 1989	Apr	DISC
>A>		+ @	90MG	N 019684	003	Sep 06, 1989	Apr	DISC

## NILUTAMIDE

TABLET;ORAL

NILANDRON

>D>	AB	+! ADVANZ PHARMA	150MG	N 020169	002	Apr 30, 1999	Apr	DISC
>A>		+ @	150MG	N 020169	002	Apr 30, 1999	Apr	DISC

NILUTAMIDE

>D>	AB	ANI PHARMS	150MG	A 207631	001	Jul 15, 2016	Apr	CHRS
>A>	AB	!	150MG	A 207631	001	Jul 15, 2016	Apr	CHRS
>A>		!	150MG	A 207631	001	Jul 15, 2016	Apr	CTEC

## NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

>D>		@ AMTA	8.5MG	A 216606	001	Apr 10, 2023	Apr	CMFD
>A>	AB		8.5MG	A 216606	001	Apr 10, 2023	Apr	CMFD
>D>	AB	MYLAN	8.5MG	A 091001	001	Jan 26, 2011	Apr	DISC
>A>		@	8.5MG	A 091001	001	Jan 26, 2011	Apr	DISC
>D>	AB		17MG	A 091001	002	Jan 26, 2011	Apr	DISC
>A>		@	17MG	A 091001	002	Jan 26, 2011	Apr	DISC
>D>		!	20MG	A 079051	001	Jul 25, 2008	Apr	DISC
>A>		@	20MG	A 079051	001	Jul 25, 2008	Apr	DISC
>D>			25.5MG	A 091001	003	Jan 26, 2011	Apr	DISC
>A>		@	25.5MG	A 091001	003	Jan 26, 2011	Apr	DISC
>D>			30MG	A 079051	002	Jul 25, 2008	Apr	DISC
>A>		@	30MG	A 079051	002	Jul 25, 2008	Apr	DISC
>D>		!	40MG	A 079051	003	Jul 25, 2008	Apr	DISC
>A>		@	40MG	A 079051	003	Jul 25, 2008	Apr	DISC
		SULAR						
>D>	AB	+! AZURITY	8.5MG	N 020356	008	Jan 02, 2008	Apr	CTEC
>A>		+!	8.5MG	N 020356	008	Jan 02, 2008	Apr	CTEC
>A>	AB	+!	8.5MG	N 020356	008	Jan 02, 2008	Apr	CTEC

## NITROFURANTOIN

SUSPENSION;ORAL

NITROFURANTOIN

>D>	AB	AMNEAL PHARMS	25MG/5ML	A 201679	001	May 11, 2011	Apr	DISC
>A>		@	25MG/5ML	A 201679	001	May 11, 2011	Apr	DISC

## NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

>D>		@ ATHEM	25MG	A 074336	001	Jan 25, 1995	Apr	CAHN
>D>		@	50MG	A 074336	002	Jan 25, 1995	Apr	CAHN
>D>		@	100MG	A 074336	003	Jan 25, 1995	Apr	CAHN
>A>		@ POM PHARMA	25MG	A 074336	001	Jan 25, 1995	Apr	CAHN
>A>		@	50MG	A 074336	002	Jan 25, 1995	Apr	CAHN
>A>		@	100MG	A 074336	003	Jan 25, 1995	Apr	CAHN

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

NUSINERSEN SODIUM

SOLUTION; INTRATHECAL  
SPINRAZA

>A>	+	BIOGEN IDEC	EQ 28MG BASE/5ML (EQ 5.6MG BASE/ML)	N209531	002	Mar 27, 2026	Apr	NEWA
>A>	+		EQ 50MG BASE/5ML (EQ 10MG BASE/ML)	N209531	003	Mar 27, 2026	Apr	NEWA

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

OMEGA-3-ACID ETHYL ESTERS

>D>	AB	AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	Apr	DISC
>A>	@		1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	Apr	DISC
>D>	AB	APOTEX	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A090973	001	Sep 30, 2014	Apr	DISC
>A>	@		1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A090973	001	Sep 30, 2014	Apr	DISC

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

>D>	AB	GLENMARK PHARMS LTD	20MG	A091672	002	Oct 31, 2014	Apr	CHRS
>A>	AB	!	20MG	A091672	002	Oct 31, 2014	Apr	CHRS
>D>	AB		40MG	A091672	003	Oct 31, 2014	Apr	CHRS
>A>	AB	!	40MG	A091672	003	Oct 31, 2014	Apr	CHRS
>D>	AB	SANDOZ	20MG	A075757	002	Jan 28, 2003	Apr	CHRS
>A>	AB		20MG	A075757	002	Jan 28, 2003	Apr	CHRS
>D>	AB	!	40MG	A076515	001	Jan 21, 2009	Apr	CHRS
>A>	AB		40MG	A076515	001	Jan 21, 2009	Apr	CHRS

ORFORGLIPRON CALCIUM

TABLET; ORAL

FOUNDAYO

>A>	+	ELI LILLY AND CO	EQ 0.8MG BASE	N220934	001	Apr 01, 2026	Apr	NEWA
>A>	+		EQ 2.5MG BASE	N220934	002	Apr 01, 2026	Apr	NEWA
>A>	+		EQ 5.5MG BASE	N220934	003	Apr 01, 2026	Apr	NEWA
>A>	+		EQ 9MG BASE	N220934	004	Apr 01, 2026	Apr	NEWA
>A>	+		EQ 14.5MG BASE	N220934	005	Apr 01, 2026	Apr	NEWA
>A>	+		EQ 17.2MG BASE	N220934	006	Apr 01, 2026	Apr	NEWA

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

OSELTAMIVIR PHOSPHATE

>D>	AB	CEDIPROF INC	EQ 30MG BASE	A217451	001	Dec 03, 2024	Apr	DISC
>A>	@		EQ 30MG BASE	A217451	001	Dec 03, 2024	Apr	DISC
>D>	AB		EQ 45MG BASE	A217451	002	Dec 03, 2024	Apr	DISC
>A>	@		EQ 45MG BASE	A217451	002	Dec 03, 2024	Apr	DISC
>D>	AB		EQ 75MG BASE	A217451	003	Dec 03, 2024	Apr	DISC
>A>	@		EQ 75MG BASE	A217451	003	Dec 03, 2024	Apr	DISC
>D>	AB	UPSHER SMITH LABS	EQ 30MG BASE	A213437	001	Jan 22, 2026	Apr	DISC
>A>	@		EQ 30MG BASE	A213437	001	Jan 22, 2026	Apr	DISC
>D>	AB		EQ 45MG BASE	A213437	002	Jan 22, 2026	Apr	DISC
>A>	@		EQ 45MG BASE	A213437	002	Jan 22, 2026	Apr	DISC
>D>	AB		EQ 75MG BASE	A213437	003	Jan 22, 2026	Apr	DISC
>A>	@		EQ 75MG BASE	A213437	003	Jan 22, 2026	Apr	DISC

OXALIPLATIN

INJECTABLE; INTRAVENOUS

OXALIPLATIN

>D>	AP	ACTAVIS	50MG/10ML (5MG/ML)	A204880	001	Mar 05, 2018	Apr	DISC
>A>	@		50MG/10ML (5MG/ML)	A204880	001	Mar 05, 2018	Apr	DISC
>D>	AP		100MG/20ML (5MG/ML)	A204880	002	Mar 05, 2018	Apr	DISC
>A>	@		100MG/20ML (5MG/ML)	A204880	002	Mar 05, 2018	Apr	DISC
>D>	AP	HENGRUI PHARMA	50MG/10ML (5MG/ML)	A203869	001	Jun 18, 2014	Apr	DISC
>A>	@		50MG/10ML (5MG/ML)	A203869	001	Jun 18, 2014	Apr	DISC
>D>	AP		100MG/20ML (5MG/ML)	A203869	002	Jun 18, 2014	Apr	DISC

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

## OXALIPLATIN

INJECTABLE; INTRAVENOUS

OXALIPLATIN

>A>		@	100MG/20ML (5MG/ML)	A203869	002	Jun 18, 2014	Apr	DISC
>D>	AP	NOVAST LABS	100MG/20ML (5MG/ML)	A207562	002	Oct 16, 2018	Apr	DISC
>A>		@	100MG/20ML (5MG/ML)	A207562	002	Oct 16, 2018	Apr	DISC
>D>	AP	+! TEVA PHARMS	50MG/10ML (5MG/ML)	N022160	001	Aug 07, 2009	Apr	DISC
>A>		+ @	50MG/10ML (5MG/ML)	N022160	001	Aug 07, 2009	Apr	DISC
>D>	AP	+!	100MG/20ML (5MG/ML)	N022160	002	Aug 07, 2009	Apr	DISC
>A>		+ @	100MG/20ML (5MG/ML)	N022160	002	Aug 07, 2009	Apr	DISC

## OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

>A>	AB	UMEDICA LABS PVT	150MG	A218341	001	Apr 29, 2026	Apr	NEWA
>A>	AB		300MG	A218341	002	Apr 29, 2026	Apr	NEWA
>A>	AB		600MG	A218341	003	Apr 29, 2026	Apr	NEWA

## OXICONAZOLE NITRATE

LOTION; TOPICAL

OXISTAT

>D>		+! ANI PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992	Apr	DISC
>A>		+ @	EQ 1% BASE	N020209	001	Sep 30, 1992	Apr	DISC

## PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

PALIPERIDONE

>D>	AB	APOTEX	3MG	A203279	001	Jan 26, 2026	Apr	DISC
>A>		@	3MG	A203279	001	Jan 26, 2026	Apr	DISC
>D>	AB		6MG	A203279	002	Jan 26, 2026	Apr	DISC
>A>		@	6MG	A203279	002	Jan 26, 2026	Apr	DISC
>D>	AB		9MG	A203279	003	Jan 26, 2026	Apr	DISC
>A>		@	9MG	A203279	003	Jan 26, 2026	Apr	DISC

## PANTOPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

PANTOPRAZOLE SODIUM

>A>	AP	SHUANGCHENG	EQ 40MG BASE/VIAL	A219973	001	Apr 22, 2026	Apr	NEWA
-----	----	-------------	-------------------	---------	-----	--------------	-----	------

## PARICALCITOL

CAPSULE; ORAL

ZEMPLAR

>D>	AB	+ ABBVIE	2MCG	N021606	002	May 26, 2005	Apr	DISC
>A>		+ @	2MCG	N021606	002	May 26, 2005	Apr	DISC

SOLUTION; INTRAVENOUS

PARICALCITOL

>D>	AP	CAPLIN	0.002MG/ML (0.002MG/ML)	A204910	001	Aug 17, 2016	Apr	DISC
>A>		@	0.002MG/ML (0.002MG/ML)	A204910	001	Aug 17, 2016	Apr	DISC
>D>	AP		0.005MG/ML (0.005MG/ML)	A204910	002	Aug 17, 2016	Apr	DISC
>A>		@	0.005MG/ML (0.005MG/ML)	A204910	002	Aug 17, 2016	Apr	DISC
>D>	AP		0.01MG/2ML (0.005MG/ML)	A204910	003	Aug 17, 2016	Apr	DISC
>A>		@	0.01MG/2ML (0.005MG/ML)	A204910	003	Aug 17, 2016	Apr	DISC

## PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

PENTAMIDINE ISETHIONATE

>A>	AN	PAI HOLDINGS	300MG/VIAL	A206667	001	Apr 24, 2019	Apr	CAHN
>D>	AN	SETON PHARMS	300MG/VIAL	A206667	001	Apr 24, 2019	Apr	CAHN

INJECTABLE; INJECTION

PENTAMIDINE ISETHIONATE

>A>	AP	PAI HOLDINGS	300MG/VIAL	A206666	001	Sep 28, 2017	Apr	CAHN
>D>	AP	PHARMOBEDIANT	300MG/VIAL	A206982	001	Mar 17, 2022	Apr	DISC
>A>		@	300MG/VIAL	A206982	001	Mar 17, 2022	Apr	DISC
>D>	AP	SETON PHARMS	300MG/VIAL	A206666	001	Sep 28, 2017	Apr	CAHN

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

PILOCARPINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PILOCARPINE HYDROCHLORIDE

>D>	AB	AMNEAL	1.25%	A217733	001	Apr 28, 2025	Apr	CHRS
>A>	AB	!	1.25%	A217733	001	Apr 28, 2025	Apr	CHRS
>A>		!	1.25%	A217733	001	Apr 28, 2025	Apr	CTEC
>D>		VUITY						
>D>	AB	+! ABBVIE	1.25%	N214028	001	Oct 28, 2021	Apr	DISC
>A>		+ @	1.25%	N214028	001	Oct 28, 2021	Apr	DISC

PIMOZIDE

TABLET;ORAL

PIMOZIDE

>A>	AB	NOVITIUM PHARMA	1MG	A219897	001	Apr 13, 2026	Apr	NEWA
>A>	AB		2MG	A219897	002	Apr 13, 2026	Apr	NEWA
>D>		PH HEALTH	1MG	A204521	001	Sep 28, 2015	Apr	CTEC
>A>	AB		1MG	A204521	001	Sep 28, 2015	Apr	CTEC
>D>		!	2MG	A204521	002	Sep 28, 2015	Apr	CTEC
>A>	AB	!	2MG	A204521	002	Sep 28, 2015	Apr	CTEC

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

>D>	AP	SANDOZ	EQ 2GM BASE/VIAL;EQ 250MG	A065363	001	Oct 21, 2010	Apr	DISC
>A>		@	BASE/VIAL					
>A>			EQ 2GM BASE/VIAL;EQ 250MG	A065363	001	Oct 21, 2010	Apr	DISC
>D>	AP		BASE/VIAL					
>D>	AP		EQ 3GM BASE/VIAL;EQ 375MG	A065363	002	Oct 21, 2010	Apr	DISC
>A>		@	BASE/VIAL					
>A>			EQ 3GM BASE/VIAL;EQ 375MG	A065363	002	Oct 21, 2010	Apr	DISC
>D>	AP		BASE/VIAL					
>D>	AP		EQ 4GM BASE/VIAL;EQ 500MG	A065363	003	Oct 21, 2010	Apr	DISC
>A>		@	BASE/VIAL					
>A>			EQ 4GM BASE/VIAL;EQ 500MG	A065363	003	Oct 21, 2010	Apr	DISC
>A>			BASE/VIAL					

PIRFENIDONE

CAPSULE;ORAL

PIRFENIDONE

>A>	AB	AUROBINDO PHARMA	267MG	A212597	001	Apr 20, 2026	Apr	NEWA
-----	----	------------------	-------	---------	-----	--------------	-----	------

PODOFILOX

SOLUTION;TOPICAL

CONDYLOX

>D>								
>D>	AT	+! TEVA BRANDED PHARM	0.5%	N019795	001	Dec 13, 1990	Apr	DISC
>A>		+ @	0.5%	N019795	001	Dec 13, 1990	Apr	DISC
>D>		PODOFILOX						
>D>	AT	PADAGIS US	0.5%	A075600	001	Jan 29, 2002	Apr	CHRS
>A>	AT	!	0.5%	A075600	001	Jan 29, 2002	Apr	CHRS
>A>		!	0.5%	A075600	001	Jan 29, 2002	Apr	CTEC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

TRILYTE

>D>		@ AUROBINDO PHARMA USA	420GM/BOT;1.48GM/BOT;5.72G	A076491	001	Feb 05, 2004	Apr	CMFD
>A>	AA		M/BOT;11.2GM/BOT					
>A>	AA		420GM/BOT;1.48GM/BOT;5.72G	A076491	001	Feb 05, 2004	Apr	CMFD
>A>			M/BOT;11.2GM/BOT					

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

>D>		@ QUAGEN	120GM/PACKET;1.49GM/PACKET	N018983	005	Oct 26, 1984	Apr	CRLD
>A>		+ @	;3.36GM/PACKET;2.92GM/PACK					
>A>			ET;11.36GM/PACKET					
>A>		+ @	120GM/PACKET;1.49GM/PACKET	N018983	005	Oct 26, 1984	Apr	CRLD
>A>			;3.36GM/PACKET;2.92GM/PACK					
>A>			ET;11.36GM/PACKET					
>D>		@	227.1GM/PACKET;2.82GM/PACK	N018983	004	Oct 26, 1984	Apr	CRLD
>D>			ET;6.36GM/PACKET;5.53GM/PA					
>D>			CKET;21.5					

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL  
COLYTE

GM/PACKET

>A>	+ @		227.1GM/PACKET;2.82GM/PACK N018983 004 Oct 26, 1984 Apr CRLD
			ET;6.36GM/PACKET;5.53GM/PA
			CKET;21.5GM/PACKET
>D>	@		227.1GM/BOT;2.82GM/BOT;6.3 N018983 010 Jan 31, 1989 Apr CRLD
			6GM/BOT;5.53GM/BOT;21.5GM/
			BOT
>A>	+ @		227.1GM/BOT;2.82GM/BOT;6.3 N018983 010 Jan 31, 1989 Apr CRLD
			6GM/BOT;5.53GM/BOT;21.5GM/
			BOT
>D>	@		240GM/BOT;2.98GM/BOT;6.72G N018983 007 Jun 12, 1987 Apr CRLD
			M/BOT;5.84GM/BOT;22.72GM/B
			OT
>A>	+ @		240GM/BOT;2.98GM/BOT;6.72G N018983 007 Jun 12, 1987 Apr CRLD
			M/BOT;5.84GM/BOT;22.72GM/B
			OT
>D>	@		360GM/PACKET;4.47GM/PACKET N018983 006 Oct 26, 1984 Apr CRLD
			;10.08GM/PACKET;8.76GM/PAC
			KET;34.08GM/PACKET
>A>	+ @		360GM/PACKET;4.47GM/PACKET N018983 006 Oct 26, 1984 Apr CRLD
			;10.08GM/PACKET;8.76GM/PAC
			KET;34.08GM/PACKET
>A>	+ @	STRIDES PHARMA INTL	120GM/PACKET;1.49GM/PACKET N018983 005 Oct 26, 1984 Apr CAHN
			;3.36GM/PACKET;2.92GM/PACK
			ET;11.36GM/PACKET
>A>	+ @		227.1GM/PACKET;2.82GM/PACK N018983 004 Oct 26, 1984 Apr CAHN
			ET;6.36GM/PACKET;5.53GM/PA
			CKET;21.5GM/PACKET
>A>	+ @		227.1GM/BOT;2.82GM/BOT;6.3 N018983 010 Jan 31, 1989 Apr CAHN
			6GM/BOT;5.53GM/BOT;21.5GM/
			BOT
>A>	+ @		240GM/BOT;2.98GM/BOT;6.72G N018983 007 Jun 12, 1987 Apr CAHN
			M/BOT;5.84GM/BOT;22.72GM/B
			OT
>A>	+ @		360GM/PACKET;4.47GM/PACKET N018983 006 Oct 26, 1984 Apr CAHN
			;10.08GM/PACKET;8.76GM/PAC
			KET;34.08GM/PACKET
		COLYTE WITH FLAVOR PACKS	
>D>	@	QUAGEN	240GM/BOT;2.98GM/BOT;6.72G N018983 012 Oct 08, 1998 Apr CRLD
			M/BOT;5.84GM/BOT;22.72GM/B
			OT
>A>	+ @		240GM/BOT;2.98GM/BOT;6.72G N018983 012 Oct 08, 1998 Apr CRLD
			M/BOT;5.84GM/BOT;22.72GM/B
			OT
>A>	+ @	STRIDES PHARMA INTL	240GM/BOT;2.98GM/BOT;6.72G N018983 012 Oct 08, 1998 Apr CAHN
			M/BOT;5.84GM/BOT;22.72GM/B
			OT
		COLYTE-FLAVORED	
>D>	@	QUAGEN	227.1GM/BOT;2.82GM/BOT;6.3 N018983 008 Nov 14, 1991 Apr CRLD
			6GM/BOT;5.53GM/BOT;21.5GM/
			BOT
>A>	+ @		227.1GM/BOT;2.82GM/BOT;6.3 N018983 008 Nov 14, 1991 Apr CRLD
			6GM/BOT;5.53GM/BOT;21.5GM/
			BOT
>D>	@		240GM/BOT;2.98GM/BOT;6.72G N018983 009 Nov 14, 1991 Apr CRLD
			M/BOT;5.84GM/BOT;22.72GM/B
			OT
>A>	+ @		240GM/BOT;2.98GM/BOT;6.72G N018983 009 Nov 14, 1991 Apr CRLD
			M/BOT;5.84GM/BOT;22.72GM/B
			OT
>A>	+ @	STRIDES PHARMA INTL	227.1GM/BOT;2.82GM/BOT;6.3 N018983 008 Nov 14, 1991 Apr CAHN
			6GM/BOT;5.53GM/BOT;21.5GM/
			BOT
>A>	+ @		240GM/BOT;2.98GM/BOT;6.72G N018983 009 Nov 14, 1991 Apr CAHN
			M/BOT;5.84GM/BOT;22.72GM/B
			OT
		PEG 3350 AND ELECTROLYTES	
>D>		NOVEL LABS INC	240GM/BOT;2.98GM/BOT;6.72G A090186 001 Jun 01, 2009 Apr CHRS
			M/BOT;5.84GM/BOT;22.72GM/B
			OT

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL  
PEG 3350 AND ELECTROLYTES

>A> ! 240GM/BOT;2.98GM/BOT;6.72G A090186 001 Jun 01, 2009 Apr CHRS  
M/BOT;5.84GM/BOT;22.72GM/B  
OT

POSACONAZOLE

TABLET, DELAYED RELEASE;ORAL  
POSACONAZOLE

>A> AB WELDING 100MG A216326 001 Jun 20, 2023 Apr CAHN  
>D> AB WESTMINSTER PHARMS 100MG A216326 001 Jun 20, 2023 Apr CAHN

POTASSIUM CHLORIDE

FOR SOLUTION;ORAL  
POKONZA

>A> + GENUS 15MEQ N208019 004 Nov 12, 2025 Apr NEWA

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL  
PEDIAPRED

>A> AA +! PAI HOLDINGS EQ 5MG BASE/5ML N019157 001 May 28, 1986 Apr CAHN  
>D> AA +! SETON PHARM EQ 5MG BASE/5ML N019157 001 May 28, 1986 Apr CAHN

PREGABALIN

CAPSULE;ORAL  
PREGABALIN

>A> AB UNICHEM 25MG A219593 001 Apr 30, 2026 Apr NEWA  
>A> AB 50MG A219593 002 Apr 30, 2026 Apr NEWA  
>A> AB 75MG A219593 003 Apr 30, 2026 Apr NEWA  
>A> AB 100MG A219593 004 Apr 30, 2026 Apr NEWA  
>A> AB 150MG A219593 005 Apr 30, 2026 Apr NEWA  
>A> AB 200MG A219593 006 Apr 30, 2026 Apr NEWA  
>A> AB 225MG A219593 007 Apr 30, 2026 Apr NEWA  
>A> AB 300MG A219593 008 Apr 30, 2026 Apr NEWA

PROGESTERONE

GEL;VAGINAL  
CRINONE

>D> +! ABBVIE 4% N020701 001 Jul 31, 1997 Apr DISC  
>A> + @ 4% N020701 001 Jul 31, 1997 Apr DISC

INSERT;VAGINAL  
PROGESTERONE

>A> AB GLENMARK PHARMS 100MG A216363 001 Apr 08, 2026 Apr CAHN  
>D> AB GLENMARK PHARMS LTD 100MG A216363 001 Apr 08, 2026 Apr CAHN

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
PROPRANOLOL HYDROCHLORIDE

>A> AB IPCA LABS LTD 60MG A203103 001 May 01, 2026 Apr NEWA  
>A> AB 80MG A203103 002 May 01, 2026 Apr NEWA  
>A> AB 120MG A203103 003 May 01, 2026 Apr NEWA  
>A> AB 160MG A203103 004 May 01, 2026 Apr NEWA

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

>A> @ ALLIED 1MG/ML A076400 001 Feb 26, 2003 Apr CAHN  
>D> @ FOSUN PHARMA 1MG/ML A076400 001 Feb 26, 2003 Apr CAHN

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL  
QUETIAPINE FUMARATE

>D> AB MEDICAP LABS EQ 50MG BASE A202939 001 May 09, 2017 Apr CAHN  
>D> AB EQ 150MG BASE A202939 002 May 09, 2017 Apr CAHN  
>D> AB EQ 200MG BASE A202939 003 May 09, 2017 Apr CAHN  
>D> AB EQ 300MG BASE A202939 004 May 09, 2017 Apr CAHN  
>D> AB EQ 400MG BASE A202939 005 May 09, 2017 Apr CAHN  
>A> AB PLATINUM EQ 50MG BASE A202939 001 May 09, 2017 Apr CAHN  
>A> AB EQ 150MG BASE A202939 002 May 09, 2017 Apr CAHN  
>A> AB EQ 200MG BASE A202939 003 May 09, 2017 Apr CAHN  
>A> AB EQ 300MG BASE A202939 004 May 09, 2017 Apr CAHN

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL  
QUETIAPINE FUMARATE

>A>	AB		EQ 400MG BASE	A202939	005	May 09, 2017	Apr	CAHN
		TABLET;ORAL						
		QUETIAPINE FUMARATE						
>D>	AB	SUN PHARM	EQ 25MG BASE	A201190	001	Mar 27, 2012	Apr	DISC
>A>		@	EQ 25MG BASE	A201190	001	Mar 27, 2012	Apr	DISC
>D>	AB		EQ 400MG BASE	A201190	006	Mar 27, 2012	Apr	DISC
>A>		@	EQ 400MG BASE	A201190	006	Mar 27, 2012	Apr	DISC

RAMIPRIL

SOLUTION;ORAL  
VOSTALLY  
+! ROSEMONT PHARMS  
+ @

>D>			1MG/ML	N219757	001	Jul 23, 2025	Apr	DISC
>A>			1MG/ML	N219757	001	Jul 23, 2025	Apr	DISC

RANOLAZINE

GRANULE, EXTENDED RELEASE;ORAL  
ASPRUZYO SPRINKLE  
+ @ SPIL  
+ @  
GRANULES, EXTENDED RELEASE;ORAL  
ASPRUZYO SPRINKLE  
+ @ SPIL  
+ @

>A>			500MG	N216018	001	Feb 28, 2022	Apr	CDFR
>A>			1GM	N216018	002	Feb 28, 2022	Apr	CDFR
>D>			500MG	N216018	001	Feb 28, 2022	Apr	CDFR
>D>			1GM	N216018	002	Feb 28, 2022	Apr	CDFR

RIVAROXABAN

TABLET;ORAL  
RIVAROXABAN

>D>	AB	APOTEX	10MG	A208579	001	Nov 14, 2025	Apr	DISC
>A>		@	10MG	A208579	001	Nov 14, 2025	Apr	DISC
>D>	AB		15MG	A208579	002	Nov 14, 2025	Apr	DISC
>A>		@	15MG	A208579	002	Nov 14, 2025	Apr	DISC
>D>	AB		20MG	A208579	003	Nov 14, 2025	Apr	DISC
>A>		@	20MG	A208579	003	Nov 14, 2025	Apr	DISC

SELENIOS ACID

SOLUTION;INTRAVENOUS  
SELENIOS ACID

>D>	AP	RK PHARMA	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	A218536	001	Dec 31, 2025	Apr	CAHN
>D>	AP		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218536	002	Dec 31, 2025	Apr	CAHN
>A>	AP	STIRA	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	A218536	001	Dec 31, 2025	Apr	CAHN
>A>	AP		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218536	002	Dec 31, 2025	Apr	CAHN

SELEXIPAG

TABLET;ORAL  
SELEXIPAG

>A>	AB	RK PHARMA	0.2MG	A214055	001	Apr 16, 2026	Apr	NEWA
>A>	AB		0.4MG	A214055	002	Apr 16, 2026	Apr	NEWA
>A>	AB		0.6MG	A214055	003	Apr 16, 2026	Apr	NEWA
>A>	AB		0.8MG	A214055	004	Apr 16, 2026	Apr	NEWA
>A>	AB		1MG	A214055	005	Apr 16, 2026	Apr	NEWA
>A>	AB		1.2MG	A214055	006	Apr 16, 2026	Apr	NEWA
>A>	AB		1.4MG	A214055	007	Apr 16, 2026	Apr	NEWA
>A>	AB		1.6MG	A214055	008	Apr 16, 2026	Apr	NEWA

UPTRAVI

+ ACTELION

>D>			1MG	N207947	005	Dec 21, 2015	Apr	CTEC
>A>	AB		1MG	N207947	005	Dec 21, 2015	Apr	CTEC
>D>			1.2MG	N207947	006	Dec 21, 2015	Apr	CTEC
>A>	AB		1.2MG	N207947	006	Dec 21, 2015	Apr	CTEC

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

SILDENAFIL CITRATE

TABLET; ORAL

SILDENAFIL CITRATE

>D>	AB	TEVA PHARMS	EQ 20MG BASE	A 078380 001	Jan 07, 2013	Apr	DISC
>A>		@	EQ 20MG BASE	A 078380 001	Jan 07, 2013	Apr	DISC

SIROLIMUS

POWDER; INTRAVENOUS

FYARRO

>A>		+! AADI	100MG/VIAL	N 213312 001	Nov 22, 2021	Apr	CAHN
>D>		+! AADI SUB	100MG/VIAL	N 213312 001	Nov 22, 2021	Apr	CAHN

SODIUM ACETATE

SOLUTION; INTRAVENOUS

SODIUM ACETATE

>A>	AP	EXTROVIS	100MEQ/50ML (2MEQ/ML)	A 220274 001	Apr 17, 2026	Apr	NEWA
>A>	AP		200MEQ/100ML (2MEQ/ML)	A 220274 002	Apr 17, 2026	Apr	NEWA

SODIUM BICARBONATE

SOLUTION; INTRAVENOUS

SODIUM BICARBONATE

>A>	AP	ASPIRO	5MEQ/10ML (0.5MEQ/ML)	A 220788 001	Apr 15, 2026	Apr	NEWA
>A>	AP		10MEQ/10ML (1MEQ/ML)	A 220788 002	Apr 15, 2026	Apr	NEWA
>A>	AP		50MEQ/50ML (1MEQ/ML)	A 220788 003	Apr 15, 2026	Apr	NEWA

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18

>D>	AP	NUKEMED	10-200mCi/ML	A 203912 001	Apr 22, 2015	Apr	DISC
>A>		@	10-200mCi/ML	A 203912 001	Apr 22, 2015	Apr	DISC

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

SUCCINYLCHOLINE CHLORIDE

>A>	AP	NIVAGEN PHARMS INC	20MG/ML	A 211625 001	May 19, 2020	Apr	CAHN
>D>	AP	UMEDICA	20MG/ML	A 211625 001	May 19, 2020	Apr	CAHN

THALIDOMIDE

CAPSULE; ORAL

THALIDOMIDE

>A>	AB	NATCO	50MG	A 213267 002	Apr 24, 2026	Apr	NFTG
>A>	AB		100MG	A 213267 003	Apr 24, 2026	Apr	NFTG
>A>	AB		200MG	A 213267 004	Apr 24, 2026	Apr	NFTG

THALOMID

>D>		+ BRISTOL-MYERS	50MG	N 020785 001	Jul 16, 1998	Apr	CFTG
>A>	AB	+	50MG	N 020785 001	Jul 16, 1998	Apr	CFTG
>D>		+	100MG	N 020785 002	Jan 17, 2003	Apr	CFTG
>A>	AB	+	100MG	N 020785 002	Jan 17, 2003	Apr	CFTG
>D>		+!	200MG	N 020785 003	Jan 17, 2003	Apr	CFTG
>A>	AB	+!	200MG	N 020785 003	Jan 17, 2003	Apr	CFTG

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

>D>	AP	HENGRUI PHARMA	15MG/VIAL	A 209150 001	May 04, 2018	Apr	DISC
>A>		@	15MG/VIAL	A 209150 001	May 04, 2018	Apr	DISC

TICAGRELOR

TABLET; ORAL

TICAGRELOR

>A>	AB	MICRO LABS	60MG	A 208539 001	Apr 27, 2026	Apr	NEWA
>A>	AB		90MG	A 208539 002	Apr 27, 2026	Apr	NEWA

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

>D>		@ EUGIA PHARMA	EQ 1.2GM BASE/VIAL	A 217519 001	Jun 21, 2023	Apr	CMFD
>A>	AP		EQ 1.2GM BASE/VIAL	A 217519 001	Jun 21, 2023	Apr	CMFD

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

## TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE;ORAL

TOFACITINIB CITRATE

>D>	@ AJANTA PHARMA LTD	EQ 11MG BASE	A 219542	001	Aug 19, 2025	Apr	CMFD
>A>	AB	EQ 11MG BASE	A 219542	001	Aug 19, 2025	Apr	CMFD
>D>	@ AUROBINDO PHARMA LTD	EQ 11MG BASE	A 218462	001	Jun 03, 2024	Apr	CMFD
>A>	AB	EQ 11MG BASE	A 218462	001	Jun 03, 2024	Apr	CMFD
>D>	@ DEXCEL	EQ 11MG BASE	A 218668	001	Dec 16, 2024	Apr	CMFD
>A>	AB	EQ 11MG BASE	A 218668	001	Dec 16, 2024	Apr	CMFD
>D>	@ ZYDUS PHARMS	EQ 11MG BASE	A 214264	001	Aug 19, 2021	Apr	CMFD
>A>	AB	EQ 11MG BASE	A 214264	001	Aug 19, 2021	Apr	CMFD
>D>	@	EQ 22MG BASE	A 214264	002	Aug 19, 2021	Apr	CMFD
>A>	AB	EQ 22MG BASE	A 214264	002	Aug 19, 2021	Apr	CMFD
>A>	AB	EQ 22MG BASE	A 214264	002	Aug 19, 2021	Apr	CHRS

XELJANZ XR

>D>	+! PFIZER	EQ 22MG BASE	N 208246	002	Dec 12, 2019	Apr	CTEC
>A>	AB	EQ 22MG BASE	N 208246	002	Dec 12, 2019	Apr	CTEC

TABLET;ORAL

TOFACITINIB CITRATE

>D>	@ AJANTA PHARMA LTD	EQ 10MG BASE	A 212943	001	Jun 01, 2021	Apr	CMFD
>A>	AB	EQ 10MG BASE	A 212943	001	Jun 01, 2021	Apr	CMFD
>D>	@ MICRO LABS	EQ 5MG BASE	A 209738	001	Mar 13, 2023	Apr	CMFD
>A>	AB	EQ 5MG BASE	A 209738	001	Mar 13, 2023	Apr	CMFD
>D>	@ ZYDUS PHARMS	EQ 5MG BASE	A 209829	001	Mar 13, 2023	Apr	CMFD
>A>	AB	EQ 5MG BASE	A 209829	001	Mar 13, 2023	Apr	CMFD

XELJANZ

>D>	+ PF PRISM CV	EQ 5MG BASE	N 203214	001	Nov 06, 2012	Apr	CTEC
>A>	AB	EQ 5MG BASE	N 203214	001	Nov 06, 2012	Apr	CTEC
>D>	+!	EQ 10MG BASE	N 203214	002	May 30, 2018	Apr	CTEC
>A>	AB	EQ 10MG BASE	N 203214	002	May 30, 2018	Apr	CTEC

## TOLVAPTAN

TABLET;ORAL

TOLVAPTAN

>A>	AB2	ALKEM LABS LTD	15MG	A 220147	001	Apr 21, 2026	Apr	NEWA
>A>	AB2		30MG	A 220147	002	Apr 21, 2026	Apr	NEWA
>A>	AB		45MG	A 220147	003	Apr 21, 2026	Apr	NEWA
>A>	AB2		60MG	A 220147	004	Apr 21, 2026	Apr	NEWA
>A>	AB		90MG	A 220147	005	Apr 21, 2026	Apr	NEWA

## TORSEMIDE

TABLET;ORAL

TORSEMIDE

>A>	AB	MICRO LABS	5MG	A 217239	001	May 01, 2026	Apr	NEWA
>A>	AB		10MG	A 217239	002	May 01, 2026	Apr	NEWA
>A>	AB		20MG	A 217239	003	May 01, 2026	Apr	NEWA

## TRETINOIN

GEL;TOPICAL

RETIN-A-MICRO

>D>	+! BAUSCH	0.06%	N 020475	004	Oct 23, 2017	Apr	CFTG	
>A>	AB	0.06%	N 020475	004	Oct 23, 2017	Apr	CFTG	
>A>	AB	TRETINOIN MICROSPHERE	0.06%	A 215609	002	Apr 15, 2026	Apr	NFTG

## TRIFLUOPERAZINE HYDROCHLORIDE

TABLET;ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

>D>	@ ATHEM	EQ 1MG BASE	A 040153	001	Oct 25, 1996	Apr	CAHN
>D>	@	EQ 2MG BASE	A 040153	002	Oct 25, 1996	Apr	CAHN
>D>	@	EQ 5MG BASE	A 040153	003	Oct 25, 1996	Apr	CAHN
>D>	@	EQ 10MG BASE	A 040153	004	Oct 25, 1996	Apr	CAHN
>A>	@ POM PHARMA	EQ 1MG BASE	A 040153	001	Oct 25, 1996	Apr	CAHN
>A>	@	EQ 2MG BASE	A 040153	002	Oct 25, 1996	Apr	CAHN
>A>	@	EQ 5MG BASE	A 040153	003	Oct 25, 1996	Apr	CAHN
>A>	@	EQ 10MG BASE	A 040153	004	Oct 25, 1996	Apr	CAHN

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

VALSARTAN

TABLET; ORAL

VALSARTAN

>A>	AB	LAURUS	40MG	A218897	001	Apr 21, 2026	Apr	NEWA
>A>	AB		80MG	A218897	002	Apr 21, 2026	Apr	NEWA
>A>	AB		160MG	A218897	003	Apr 21, 2026	Apr	NEWA
>A>	AB		320MG	A218897	004	Apr 21, 2026	Apr	NEWA

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL

FIRVANQ KIT

>D>	AB	+! AZURITY	EQ 25MG BASE/ML	N208910	001	Jan 26, 2018	Apr	CTEC
>A>	AA	+!	EQ 25MG BASE/ML	N208910	001	Jan 26, 2018	Apr	CTEC
>D>	AB	+!	EQ 50MG BASE/ML	N208910	002	Jan 26, 2018	Apr	CTEC
>A>	AA	+!	EQ 50MG BASE/ML	N208910	002	Jan 26, 2018	Apr	CTEC

VANCOMYCIN HYDROCHLORIDE

ALKEM LABS LTD

>D>	AB		EQ 25MG BASE/ML	A214913	001	Nov 14, 2022	Apr	CTEC
>A>	AA		EQ 25MG BASE/ML	A214913	001	Nov 14, 2022	Apr	CTEC
>D>	AB		EQ 50MG BASE/ML	A214913	002	Nov 14, 2022	Apr	CTEC
>A>	AA		EQ 50MG BASE/ML	A214913	002	Nov 14, 2022	Apr	CTEC

VASOPRESSIN

SOLUTION; INTRAVENOUS

VASOPRESSIN

>A>	AP	SANDOZ	20UNITS/ML (20UNITS/ML)	A212068	001	May 06, 2026	Apr	NEWA
>A>	AP		200UNITS/10ML (20UNITS/ML)	A212069	001	May 06, 2026	Apr	NFTG
>D>		+! PH HEALTH	200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016	Apr	CFTG
>A>	AP	+!	200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016	Apr	CFTG

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

>D>	AB	MEDICAP LABS	EQ 37.5MG BASE	A201272	001	Nov 23, 2018	Apr	CAHN
>D>	AB		EQ 75MG BASE	A201272	002	Nov 23, 2018	Apr	CAHN
>D>	AB		EQ 150MG BASE	A201272	003	Nov 23, 2018	Apr	CAHN
>A>	AB	PLATINUM	EQ 37.5MG BASE	A201272	001	Nov 23, 2018	Apr	CAHN
>A>	AB		EQ 75MG BASE	A201272	002	Nov 23, 2018	Apr	CAHN
>A>	AB		EQ 150MG BASE	A201272	003	Nov 23, 2018	Apr	CAHN

VORICONAZOLE

POWDER; INTRAVENOUS

VORICONAZOLE

>A>	AP	ZHEJIANG NOVUS	200MG/VIAL	A220078	001	May 05, 2026	Apr	NEWA
-----	----	----------------	------------	---------	-----	--------------	-----	------

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

>A>		+! ESTEVE	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Apr	CAHN
>A>		@	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Apr	CAHN
>A>		+!	500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Apr	CAHN
>A>		+!	500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Apr	CAHN
>D>		+! TERSERA	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Apr	CAHN
>D>		@	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Apr	CAHN
>D>		+!	500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Apr	CAHN
>D>		+!	500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Apr	CAHN

ZINC CHLORIDE

INJECTABLE; INJECTION

ZINC CHLORIDE

>D>	AP	RK PHARMA	EQ 1MG ZINC/ML	A217625	001	Apr 14, 2025	Apr	CAHN
>A>	AP	STIRA	EQ 1MG ZINC/ML	A217625	001	Apr 14, 2025	Apr	CAHN

ZINC SULFATE

SOLUTION; INTRAVENOUS

ZINC SULFATE

>D>	AP	RK PHARMA	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A217624	001	Jun 10, 2025	Apr	CAHN
>D>	AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A217624	002	Jun 10, 2025	Apr	CAHN
>D>	AP		EQ 30MG BASE/10ML (EQ 3MG	A217624	003	Jun 10, 2025	Apr	CAHN

# ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

## ZINC SULFATE

SOLUTION; INTRAVENOUS

ZINC SULFATE

	AP		BASE/ML)
>A>	AP	STIRA	EQ 10MG BASE/10ML (EQ 1MG A217624 001 Jun 10, 2025 Apr CAHN
			BASE/ML)
>A>	AP		EQ 25MG BASE/5ML (EQ 5MG A217624 002 Jun 10, 2025 Apr CAHN
			BASE/ML)
>A>	AP		EQ 30MG BASE/10ML (EQ 3MG A217624 003 Jun 10, 2025 Apr CAHN
			BASE/ML)

## ADDITIONS/DELETIONS FOR OTC DRUG PRODUCT LIST

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

AVAGARD

>D>	+	3M	61%;1%	N021074	001	Jun 07, 2001	Apr	CAHN
>A>	+	SOLVENTUM	61%;1%	N021074	001	Jun 07, 2001	Apr	CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION; TOPICAL

SOLUPREP S

>D>	+	3M HEALTH CARE	2%;70%	N208288	001	Aug 08, 2018	Apr	CAHN
>A>	+	SOLVENTUM	2%;70%	N208288	001	Aug 08, 2018	Apr	CAHN

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DEXTROMETHORPHAN POLISTIREX

>A>		AUROBINDO PHARMA LTD	EQ 30MG HYDROBROMIDE/5ML	A218417	001	Apr 15, 2026	Apr	NEWA
-----	--	----------------------	--------------------------	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

FLUTICASONE PROPIONATE

>D>		GLENMARK PHARMS LTD	0.05MG/SPRAY	A218742	001	Mar 16, 2026	Apr	CAHN
>A>		GLENMARK SPECLT	0.05MG/SPRAY	A218742	001	Mar 16, 2026	Apr	CAHN

IBUPROFEN

TABLET; ORAL

IBUPROFEN

>D>		AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014	Apr	DISC
>A>	@		200MG	A079233	001	Mar 18, 2014	Apr	DISC

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

DURAPREP

>D>	+	3M	EQ 0.7% IODINE;74% (6ML)	N021586	001	Sep 29, 2006	Apr	CAHN
>D>	+		EQ 0.7% IODINE;74% (26ML)	N021586	002	Sep 29, 2006	Apr	CAHN
>A>	+	SOLVENTUM	EQ 0.7% IODINE;74% (6ML)	N021586	001	Sep 29, 2006	Apr	CAHN
>A>	+		EQ 0.7% IODINE;74% (26ML)	N021586	002	Sep 29, 2006	Apr	CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

KETOTIFEN FUMARATE

>D>		APOTEX INC	EQ 0.025% BASE	A077354	001	May 09, 2006	Apr	DISC
>A>	@		EQ 0.025% BASE	A077354	001	May 09, 2006	Apr	DISC

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

>A>		ALLIED	17GM/SCOOPFUL	A090812	001	Oct 07, 2009	Apr	CAHN
>D>		LGM PHARMA	17GM/SCOOPFUL	A090812	001	Oct 07, 2009	Apr	CAHN

CURRENT MONTH ADDS/DELETES LIST NOTE:

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>.

The change code description:

NEWA	New drug product approval usually in the supplement month.
NFTG	New first time generic approval.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

\*\*Note:

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book(EOB)query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.